Dermavant Sciences Inc.
NEWS
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
It was a busy week for clinical trial news. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Tapinarof’s potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
JOBS
IN THE PRESS